Business Description
Hyloris Pharmaceuticals SA
ISIN : BE0974363955
Share Class Description:
LTS:0AB6: Ordinary SharesTotal Employee Number:
55Compare
Compare
Traded in other countries / regions
HYL.Belgium52U.Germany0AB6.UK IPO Date
2022-04-04Description
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.56 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.23 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 98.2 | |||||
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 15.1 | |||||
3-Year FCF Growth Rate | 18.7 | |||||
3-Year Book Growth Rate | -21.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 153.19 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.7 | |||||
9-Day RSI | 24.81 | |||||
14-Day RSI | 27 | |||||
3-1 Month Momentum % | 4.94 | |||||
6-1 Month Momentum % | -28.77 | |||||
12-1 Month Momentum % | -19.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.89 | |||||
Quick Ratio | 3.88 | |||||
Cash Ratio | 2.68 | |||||
Days Inventory | 84.75 | |||||
Days Sales Outstanding | 236.95 | |||||
Days Payable | 3134.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 0.18 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.74 | |||||
Operating Margin % | -106.97 | |||||
Net Margin % | -87.89 | |||||
EBITDA Margin % | -82.14 | |||||
FCF Margin % | -105.7 | |||||
OCF Margin % | -96.98 | |||||
ROE % | -21.71 | |||||
ROA % | -17 | |||||
ROIC % | -45.72 | |||||
3-Year ROIIC % | 1070.67 | |||||
ROC (Joel Greenblatt) % | -312.67 | |||||
ROCE % | -21.39 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 21.13 | |||||
PS Ratio | 17.66 | |||||
PB Ratio | 4.78 | |||||
Price-to-Tangible-Book | 6.07 | |||||
EV-to-EBIT | -17.06 | |||||
EV-to-EBITDA | -19.13 | |||||
EV-to-Revenue | 15.71 | |||||
EV-to-FCF | -15.02 | |||||
Price-to-GF-Value | 0.47 | |||||
| Price-to-Net-Current-Asset-Value | 9.55 | |||||
| Price-to-Net-Cash | 17.96 | |||||
Earnings Yield (Greenblatt) % | -5.86 | |||||
FCF Yield % | -6.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hyloris Pharmaceuticals SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.207 | ||
| EPS (TTM) (€) | -0.23 | ||
| Beta | 0.2319 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 46.39 | ||
| 14-Day RSI | 27 | ||
| 14-Day ATR (€) | 0.056452 | ||
| 20-Day SMA (€) | 4.682 | ||
| 12-1 Month Momentum % | -19.05 | ||
| 52-Week Range (€) | 4.48 - 8.22 | ||
| Shares Outstanding (Mil) | 28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hyloris Pharmaceuticals SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hyloris Pharmaceuticals SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hyloris Pharmaceuticals SA Frequently Asked Questions
What is Hyloris Pharmaceuticals SA(LTS:0AB6)'s stock price today?
The current price of LTS:0AB6 is €4.49. The 52 week high of LTS:0AB6 is €8.22 and 52 week low is €4.48.
When is next earnings date of Hyloris Pharmaceuticals SA(LTS:0AB6)?
The next earnings date of Hyloris Pharmaceuticals SA(LTS:0AB6) is .
Does Hyloris Pharmaceuticals SA(LTS:0AB6) pay dividends? If so, how much?
Hyloris Pharmaceuticals SA(LTS:0AB6) does not pay dividend.
Press Release
Articles on Hyloris Pharmaceuticals SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers